Wednesday, January 26, 2011

A negative for Dr Reddy's - Approval for OTC Allegra in US

Dr. Reddy has a ParaIV on Allegra D-24 and it seems the commericial potential of this opportunity should be adversely impacted due to OTC status for allegra family in the US.  In case, there had been no OTC approval, Allegra D-24, could have added $100m in NPV to Dr. Reddy's value, while now the benefit might just be restricted to $25m